What DalCor Pharmaceuticals does

DalCor Pharmaceuticals is a Montreal-based clinical-stage biopharmaceutical company founded in 2015 to develop dalcetrapib, a CETP (cholesteryl ester transfer protein) inhibitor repositioned as a pharmacogenetic precision medicine for cardiovascular disease. The company holds a worldwide exclusive license from Roche for dalcetrapib together with rights to the ADCY9 genetic marker (rs1967309) for use with dalcetrapib and all other CETP inhibitors, and has co-developed the cobas ADCY9 companion diagnostic with Roche Molecular Systems to identify the approximately 20% of the global population carrying the AA genotype who appear to derive clinical benefit. The lead indication targets reduction of fatal and non-fatal myocardial infarction in post-acute coronary syndrome (ACS) patients carrying the AA genotype.

DalCor's clinical pipeline is anchored by the Dal-GenE-2 (DAL-302) Phase 3 confirmatory trial, a 2,000-patient study in North America operating under a Special Protocol Assessment (SPA) agreement with the FDA. This trial follows the dal-GenE (DAL-301) Phase 3 outcomes study, which enrolled 6,149 patients across 34 countries and showed a 21% relative risk reduction in fatal and non-fatal MI in the overall cohort and a 45% RRR in the North American subset, though it did not meet its primary endpoint. Cumulatively, dalcetrapib has been administered to over 15,000 patients across the dal-Outcomes, dal-GenE, and dal-Plaque-2 programs with a reported favorable safety and tolerability profile.

The company is privately held and backed by Sanderling Ventures (which incubated DalCor as part of a Quebec biomedical program) alongside Quebec institutional capital including Caisse de dépôt et placement du Québec, Fonds de solidarité FTQ, and Investissement Québec, with additional participation from CTI Life Sciences, André Desmarais, Andes Growth, and TB Pharma. Disclosed funding totals approximately $233 million across a 2015 Series A ($50M), 2016 Series B ($100M), a May 2020 round ($3.85M), and a September 2023 Series D ($80M). DalCor has no commercial revenue and no product on the market; its business model is contingent on regulatory approval and commercialization through standard pharmaceutical channels with companion-diagnostic-driven patient identification. The company maintains offices in Montreal, Zug, Leatherhead, and Sarasota and operates with 11–50 employees.

Name

DalCor Pharmaceuticals

Legal name

DalCor Pharmaceuticals Canada Inc.

Website

https://dalcorpharma.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

DalCor Pharmaceuticals is a clinical-stage biopharmaceutical company developing dalcetrapib, a CETP inhibitor repositioned as a precision medicine for cardiovascular patients with the ADCY9 AA genotype, currently in a Phase 3 confirmatory trial under FDA SPA.

Ownership category

akta.pro rank

Product category

Cardiovascular Pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pharmacogenomics (PGx) Decision Support (HLAAANAB)

akta.pro secondary industry

Rare Cardiovascular & Vascular Disorder Therapies (HLAIAIAH)

Keywords

• Cardiovascular pharmaceuticals
• Precision medicine therapeutics
• CETP inhibitor development
• Pharmacogenetic drug development
• Clinical stage biopharmaceuticals

Headquarters

HQ city

Montréal

HQ country

Canada

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Sales: DalCor plans to commercialize dalcetrapib as a prescription cardiovascular drug following regulatory approval. The company holds worldwide exclusive license for dalcetrapib development, manufacturing, and commercialization.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

DalCor Pharmaceuticals is a clinical-stage biopharmaceutical company developing dalcetrapib, a CETP inhibitor being evaluated as the first pharmacogenetic precision medicine in cardiovascular disease. The drug specifically targets patients with the AA genotype at rs1967309 in the ADCY9 gene to reduce fatal and non-fatal myocardial infarction (MI) following acute coronary syndrome (ACS). Patient eligibility is determined through Roche's cobas ADCY9 companion diagnostic test, and efficacy is being confirmed in the Dal-GenE-2 (DAL-302) Phase III trial under an FDA SPA agreement.

Product overview

DalCor Pharmaceuticals is a biopharmaceutical company developing dalcetrapib, the first pharmacogenetic precision medicine for cardiovascular disease. The core product is dalcetrapib, a CETP inhibitor that targets patients with the AA genotype at rs1967309 in the ADCY9 gene. The company's development pipeline includes the Dal-GenE-2 (DAL-302) Phase III confirmatory trial following completion of the dal-GenE (DAL-301) trial. A companion diagnostic test developed with Roche Molecular Systems identifies eligible patients based on genetic profile.

Differentiator

Problem solved

Functional benefit

Products and services

• dalcetrapib Dalcetrapib is a CETP (cholesteryl ester transfer protein) inhibitor being developed as the first pharmacogenetic precision medicine in cardiovascular disease. It specifically targets patients with the AA genotype at rs1967309 in the ADCY9 gene (approximately 20% of the global population) to reduce fatal and non-fatal myocardial infarction following acute coronary syndrome. DalCor holds the worldwide exclusive license for development, manufacturing, and commercialization.

Quantifiable outcome

• 21% relative risk reduction in fatal and non-fatal MI in dal-GenE trial (6,149 patients, 34 countries)
• +4 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature3 records

Partnerships

Five partnerships are on record, tiered core.

• FDA (U.S. Food and Drug Administration)coreStrategic or Co-development Partner · 13 September 2023FDA agreed to Special Protocol Assessment (SPA) for Dal-GenE-2 confirmatory trial, providing regulatory alignment on trial design and endpoints. This partnership supports the potential new drug application (NDA) submission.
• Montreal Health Innovations Coordinating Centre (MHICC)coreStrategic or Co-development Partner · 26 April 2016Lead Academic Research Organization (ARO) for the dal-GenE Phase 3 clinical trial, coordinating the international clinical study across multiple countries and sites.
• MedpacecoreImplementation/ SI/ Consulting Partner · 26 April 2016Leading Clinical Research Organization (CRO) partnering with MHICC to conduct the dal-GenE Phase 3 clinical trial across 680+ sites in 32 countries.
• Roche (Molecular Diagnostics)coreTechnology or Integration · 9 June 2015Roche entered into an agreement to develop a companion diagnostic (CDx) test for dalcetrapib that identifies patients with a specific genetic variation who have experienced recent Acute Coronary Syndrome. The test is used in clinical trials to determine patient eligibility.
• Montreal Heart Institute (MHI)coreStrategic or Co-development Partner · 8 June 2015DalCor collaborated with Montreal Heart Institute scientists who discovered the genetic marker (rs1967309 in ADCY9 gene) that predicts response to dalcetrapib. MHI leads the dal-GenE clinical trial as the lead academic research organization. Dr. Jean-Claude Tardif serves as principal investigator and holds the Canada Research Chair in personalized medicine at MHI.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• NewAmsterdam Pharma: Clinical-stage biotech developing obicetrapib, another CETP inhibitor in Phase 3 for cardiovascular outcomes in high-risk patients. Most direct competitor to DalCor with same mechanism, similar stage of development, and overlapping target population.
• Esperion Therapeutics: Commercial-stage biotech focused on lipid-lowering therapies including bempedoic acid (Nexletol) for CV risk reduction in statin-intolerant patients. Comparable as a focused lipid-CV company developing oral therapies targeting residual cardiovascular risk.
• Amarin Corporation: Specialty pharma company commercializing icosapent ethyl (Vascepa) for cardiovascular risk reduction in high-triglyceride patients. Comparable as a focused CV outcomes company with a prescription drug targeting a specific patient subpopulation for residual risk reduction.
• Madrigal Pharmaceuticals: Late-stage pharma company developing resmetirom (Rezdiffra) for MASH/NASH with cardiovascular outcomes benefits. Comparable as a focused metabolic-CV drug developer with late-stage clinical assets targeting specific patient populations.
• Ionis Pharmaceuticals: Antisense oligonucleotide platform company with pelacarsen in Phase 3 (Lp(a) HORIZON trial) targeting Lp(a) for CV risk reduction. Comparable as a precision medicine CV drug developer targeting genetically-defined lipid populations.

Emerging players

• Verve Therapeutics: Clinical-stage genetic medicine company developing in vivo gene editing therapies for cardiovascular disease, including VERVE-101 targeting PCSK9. Comparable as a precision genetic medicine company targeting cardiovascular risk through novel mechanisms.
• Tenaya Therapeutics: Clinical-stage genetic medicines company developing gene therapies and precision medicines for heart disease, including hypertrophic cardiomyopathy and heart failure. Comparable as a precision medicine company targeting specific genetic subtypes of cardiovascular disease.
• BridgeBio Pharma: Clinical-stage precision medicine company with cardiovascular programs including acoramidis for transthyretin amyloid cardiomyopathy. Comparable as a precision medicine biotech developing therapies for genetically-defined patient populations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/dalcor-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DalCor Pharmaceuticals